SPHRY
Price
$0.59
Change
-$0.05 (-7.81%)
Updated
Apr 3 closing price
Capitalization
24.88M
52 days until earnings call
VBIZF
Price
$0.30
Change
+$0.01 (+3.45%)
Updated
Mar 25 closing price
Capitalization
457.7M
Ad is loading...

SPHRY vs VBIZF

Header iconSPHRY vs VBIZF Comparison
Open Charts SPHRY vs VBIZFBanner chart's image
Starpharma Holdings
Price$0.59
Change-$0.05 (-7.81%)
Volume$142
Capitalization24.88M
Viva Biotech Holdings
Price$0.30
Change+$0.01 (+3.45%)
Volume$768
Capitalization457.7M
SPHRY vs VBIZF Comparison Chart
Loading...
View a ticker or compare two or three
VS
SPHRY vs. VBIZF commentary
Apr 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SPHRY is a Hold and VBIZF is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 07, 2025
Stock price -- (SPHRY: $0.59 vs. VBIZF: $0.30)
Brand notoriety: SPHRY and VBIZF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SPHRY: 8% vs. VBIZF: 15%
Market capitalization -- SPHRY: $24.88M vs. VBIZF: $457.7M
SPHRY [@Biotechnology] is valued at $24.88M. VBIZF’s [@Biotechnology] market capitalization is $457.7M. The market cap for tickers in the [@Biotechnology] industry ranges from $283.79B to $0. The average market capitalization across the [@Biotechnology] industry is $2.07B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SPHRY’s FA Score shows that 0 FA rating(s) are green whileVBIZF’s FA Score has 1 green FA rating(s).

  • SPHRY’s FA Score: 0 green, 5 red.
  • VBIZF’s FA Score: 1 green, 4 red.
According to our system of comparison, VBIZF is a better buy in the long-term than SPHRY.

Price Growth

SPHRY (@Biotechnology) experienced а -6.35% price change this week, while VBIZF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -11.00%. For the same industry, the average monthly price growth was -16.69%, and the average quarterly price growth was -18.23%.

Reported Earning Dates

SPHRY is expected to report earnings on May 28, 2025.

Industries' Descriptions

@Biotechnology (-11.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

FUNDAMENTALS
Fundamentals
VBIZF($458M) has a higher market cap than SPHRY($24.9M). VBIZF YTD gains are higher at: 322.144 vs. SPHRY (-8.285).
SPHRYVBIZFSPHRY / VBIZF
Capitalization24.9M458M5%
EBITDA-13.7MN/A-
Gain YTD-8.285322.144-3%
P/E RatioN/A36.26-
Revenue2.98MN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
SPHRY: Fundamental Ratings
SPHRY
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
36
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
94
PRICE GROWTH RATING
1..100
81
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
RSI
ODDS (%)
Stochastic
ODDS (%)
Momentum
ODDS (%)
MACD
ODDS (%)
TrendWeek
ODDS (%)
TrendMonth
ODDS (%)
Advances
ODDS (%)
Declines
ODDS (%)
BollingerBands
ODDS (%)
Aroon
ODDS (%)
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
JRONY44.72-0.75
-1.64%
Jeronimo Martins, SGPS, SA
XYIGY18.35-0.75
-3.93%
Xinyi Glass Holdings Ltd.
ZOMDF0.05-0.01
-9.57%
Zomedica Corp
CYTOF0.06-0.01
-16.40%
Altamira Therapeutics Ltd.
MQBKY98.76-19.88
-16.76%
Macquarie Group, Ltd.

SPHRY and

Correlation & Price change

A.I.dvisor tells us that SPHRY and VACBF have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SPHRY and VACBF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPHRY
1D Price
Change %
SPHRY100%
N/A
VACBF - SPHRY
29%
Poorly correlated
N/A
TTNP - SPHRY
27%
Poorly correlated
-6.85%
SPHRF - SPHRY
25%
Poorly correlated
N/A
ASPHF - SPHRY
22%
Poorly correlated
N/A
INM - SPHRY
21%
Poorly correlated
-11.43%
More

VBIZF and

Correlation & Price change

A.I.dvisor indicates that over the last year, VBIZF has been loosely correlated with SMMT. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if VBIZF jumps, then SMMT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VBIZF
1D Price
Change %
VBIZF100%
N/A
SMMT - VBIZF
42%
Loosely correlated
-8.20%
BCLI - VBIZF
35%
Loosely correlated
-6.50%
AKBLF - VBIZF
24%
Poorly correlated
N/A
ACHL - VBIZF
24%
Poorly correlated
N/A
SPHRY - VBIZF
11%
Poorly correlated
N/A
More